Loading...

APC anti-mouse NK-1.1 Antibody

Pricing & Availability
Clone
PK136 (See other available formats)
Regulatory Status
RUO
Other Names
NKR-P1C, NKR-P1B, Ly-55, CD161, CD161b, CD161c
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
PK136_APC_1_110210
C57BL/6 mouse splenocytes were stained with CD49b (DX5) FITC and NK1.1 (clone PK136) APC (top) or mouse IgG2a APC isotype control (bottom).
  • PK136_APC_1_110210
    C57BL/6 mouse splenocytes were stained with CD49b (DX5) FITC and NK1.1 (clone PK136) APC (top) or mouse IgG2a APC isotype control (bottom).
  • PK136_APC_2_110210
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
108709 25 µg £61
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108710 100 µg £200
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
NK-1+ cells from mouse spleen and bone marrow
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The NK-1.1 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, complement-dependent cytotoxicity3, in vivo depletion4,5,9,10, mediation of in vitro redirected lysis6, blocking of NK cell function7, induction of proliferation8, immunohistochemical staining of frozen sections11, immunofluorescence microscopy11, and spatial biology (IBEX)16,17. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 108712).

Application References

(PubMed link indicates BioLegend citation)
  1. Carlyle JR, et al. 1999. J. Immunol. 162:5917. (IP)
  2. Sentman CL, et al. 1989. Hybridoma 8:605. (IP)
  3. Koo GC, et al. 1984. Hybridoma 3:301. (Cyt)
  4. Sentman CL, et al. 1989. J. Immunol. 142:1847. (Deplete)
  5. Koo GC, et al. 1986. J. Immunol. 137:3742. (Deplete)
  6. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  7. Kung SK, et al. 1999. J. Immunol. 162:5876. (Block)
  8. Reichlin A, et al. 1998. Immunol. Cell Biol. 76:143.
  9. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
  10. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (Deplete)
  11. Kanwar JR, et al. 2001. J. Natl. Cancer Inst. 93:1541. (IHC, IF)
  12. Kroemer A, et al. 2008. J. Immunol. 180:7818. PubMed
  13. Kim JY, et al. 2009. Exp Mol Med. 30:288. PubMed
  14. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  15. Lee H, et al. 2014. Invest Ophthalmol Vis Sci. 55:2885. PubMed
  16. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  2. Pi C, et al. 2022. Cancers (Basel). 14:. PubMed
  3. Schroeter CB, et al. 2022. J Neuroinflammation. 19:270. PubMed
  4. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  5. Roussel-Queval A, et al. 2023. STAR Protoc. 4:102119. PubMed
  6. Wang YC, et al. 2023. J Exp Med. 220:. PubMed
  7. Wang JX, et al. 2023. JCI Insight. 8:. PubMed
  8. Yin C, et al. 2023. Sci Rep. 13:3903. PubMed
  9. Koyama M, et al. 2015. J Exp Med. 212: 1303 - 1321. PubMed
  10. Zhao D, et al. 2021. Innate Immun. 27:533. PubMed
  11. Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed
  12. Furrer R, et al. 2021. Sci Adv. 7:eabi4852. PubMed
  13. Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed
  14. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  15. Zhang H, et al. 2022. Eur J Immunol. 52:978. PubMed
  16. Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed
  17. Liu W, et al. 2022. Biomedicines. 10: . PubMed
  18. Simpson AP, et al. 2022. Cell Rep. 40:111099. PubMed
  19. Hao J, et al. 2022. Cell Rep. 41:111804. PubMed
  20. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  21. Zhu X, et al. 2023. Front Immunol. 14:1114802. PubMed
  22. Kuehm LM, et al. 2021. Cancer Immunol Res. 9:227. PubMed
  23. Leick MB, et al. 2022. Cancer Cell. 40:494. PubMed
  24. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  25. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  26. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  27. van Vloten JP, et al. 2022. J Immunother Cancer. 10:. PubMed
  28. Symeonidou V, et al. 2021. Cell Rep. 37:109900. PubMed
  29. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  30. Wilson RP, et al. 2019. PLoS Pathog. 15:e1007745. PubMed
  31. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  32. Shen T, et al. 2019. Cell Death Discov. 5:123. PubMed
  33. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  34. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  35. Zhao J, et al. 2019. Nat Commun. 10:899. PubMed
  36. Neumann AM et al. 2017. PloS one. 12(11):e0187330 . PubMed
  37. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  38. Sun SJ, et al. 2022. Commun Biol. 5:867. PubMed
  39. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
  40. Liang Y, et al. 2020. J Immunol. 204:2984. PubMed
  41. Chen WS, et al. 2021. Cell Rep. 37:109974. PubMed
  42. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  43. Ohtsuki T, et al. 2016. J Virol. 90: 300 - 307. PubMed
  44. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  45. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
  46. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  47. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  48. Hoffman D, et al. 2021. Immunity. 54:2712. PubMed
  49. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  50. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  51. Janakiram N, et al. 2016. Sci Rep. 6:37046. PubMed
  52. Bourn JR, et al. 2021. Cancer Lett. 503:75. PubMed
  53. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  54. Hirata Y, et al. 2015. PLoS One. 10: 0141785. PubMed
  55. Wei SC, et al. 2020. Cancer Discov. . PubMed
  56. Dos Santos Dias L, et al. 2021. PLoS Pathog. e1009324:17. PubMed
  57. Kotfis K, et al. 2020. British Journal of Pharmacology. 49(1):66-72. PubMed
  58. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  59. Hernández–Santos N, et al. 2018. Cell Host Microbe. 1.313194444. PubMed
  60. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  61. Haase C, et al. 2022. Nat Methods. 19:1622. PubMed
  62. Guo L, et al. 2021. Front Immunol. 12:785457. PubMed
  63. Xu J et al. 2018. Cell. 173(3):762-775 . PubMed
  64. Zenker S, et al. 2014. J Immunol. 192:2830. PubMed
  65. Ray A, et al. 2015. PLoS One. 10: 0137314. PubMed
  66. Satoh M, et al. 2016. Sci Rep. 6:28473. PubMed
  67. Lehmann M, et al. 2016. J Leukoc Biol. 99: 1057 - 1064. PubMed
  68. Hutter K, et al. 2020. FEBS J. . PubMed
  69. Progatzky F, et al. 2021. Nature. 599:125. PubMed
  70. Textor A, et al. 2014. Cancer Res. 74:6769. PubMed
  71. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
  72. Stotesbury C, et al. 2020. J Immunol. 204:1582. PubMed
  73. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  74. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  75. Kim S, et al. 2021. Elife. 10:. PubMed
  76. Stifter SA, et al. 2019. Cell Rep. 29:3539. PubMed
  77. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  78. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  79. Dobson HE, et al. 2020. Mucosal Immunol. 0.901388889. PubMed
  80. Lim S, et al. 2016. PLoS One. 11: 0155689. PubMed
  81. Solaymani-Mohammadi S, et al. 2016. J Leukoc Biol. 99: 475 - 482. PubMed
  82. Ballet R, et al. 2014. PLoS Pathog. 10:1004550. PubMed
  83. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  84. Terhorst D, et al. 2015. J Immunol. 195: 4953 - 4961. PubMed
  85. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  86. DiToro D, et al. 2020. Immunity. 650:52. PubMed
  87. Tuong ZK, et al. 2021. iScience. 24:103326. PubMed
  88. Yu H, et al. 2021. Front Oncol. 11:736882. PubMed
  89. Wüthrich M, et al. 2021. MBio. 12:e0201821. PubMed
  90. Kohn EM, et al. 2022. J Immunol. 208:1417. PubMed
  91. Zhang P, et al. 2022. Nat Commun. 13:1588. PubMed
  92. Burgener SS, et al. 2019. Cell Rep. 27:3646. PubMed
  93. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  94. Tsuzuki S, et al. 2015. Int Immunol. 10.1093/intimm/dxv058. PubMed
  95. Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
  96. Zhang H, et al. 2017. Immunol Cell Biol. 10.1038/icb.2017.11. PubMed
  97. Dhar P, et al. 2021. Commun Biol. 4:905. PubMed
  98. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  99. Woodring T, et al. 2022. iScience. 25:104934. PubMed
  100. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  101. Huang W, et al. 2014. J Leukoc Biol. 96:55. PubMed
  102. Xu JL, et al. 2022. Front Pharmacol. 13:911663. PubMed
  103. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  104. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  105. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  106. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  107. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  108. Peng V, et al. 2022. Nat Immunol. 23:619. PubMed
  109. Stotesbury C, et al. 2020. Aging Cell. 19:e13170. PubMed
  110. Tomita T, et al. 2021. Nat Commun. 12:3655. PubMed
  111. Liu CF, et al. 2017. Front Immunol. 1.445833333. PubMed
  112. Zhang S, et al. 2016. PLoS Pathog. 12: 1005617. PubMed
  113. Kujur W, et al. 2020. PLoS Pathog. 16:e1009132. PubMed
  114. Gawish R, et al. 2022. Elife. 11:. PubMed
  115. Nabekura T, et al. 2020. Immunity. 96:52. PubMed
  116. Schmidts A, et al. 2020. J Immunother Cancer. 8:. PubMed
  117. Hester AK, et al. 2022. Cell Rep. 38:110363. PubMed
  118. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
RRID
AB_313396 (BioLegend Cat. No. 108709)
AB_313396 (BioLegend Cat. No. 108710)

Antigen Details

Structure
NKR-P1 gene family
Distribution

NK and NK-T cells in the NK1.1 mouse strains (C57BL, FVB/N, NZB)

Function
NK cell activation, IFN-γ production, cytotoxic granule release
Cell Type
NK cells, NKT cells
Biology Area
Immunology, Innate Immunity
Antigen References

1. Lanier LL. 1997. Immunity 6:371.
2. Yokoyama WM, et al. 1993. Ann. Rev. Immunol. 11:613.
3. Koo GC, et al. 1986. J. Immunol. 137:3742.
4. Giorda R, et al. 1991. J. Immunol. 147:1701.

Gene ID
17059 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
NK-1.1
Specificity Alt (DOES NOT SHOW ON TDS):
NK-1.1
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about NK-1.1 on UniProt.org

Other Formats

View All NK-1.1 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse NK-1.1 PK136 FC
Biotin anti-mouse NK-1.1 PK136 FC
FITC anti-mouse NK-1.1 PK136 FC
PE anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
PE/Cyanine7 anti-mouse NK-1.1 PK136 FC
PE/Cyanine5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 488 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 647 anti-mouse NK-1.1 PK136 FC
Pacific Blue™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 711™ anti-mouse NK-1.1 PK136 FC
APC/Cyanine7 anti-mouse NK-1.1 PK136 FC
PerCP anti-mouse NK-1.1 PK136 FC
PerCP/Cyanine5.5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 700 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 421™ anti-mouse NK-1.1 PK136 FC,SB
Brilliant Violet 570™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 650™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 510™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 605™ anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 (Maxpar® Ready) PK136 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 785™ anti-mouse NK-1.1 PK136 FC
APC/Fire™ 750 anti-mouse NK-1.1 PK136 FC
TotalSeq™-A0118 anti-mouse NK-1.1 PK136 PG
Ultra-LEAF™ Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
TotalSeq™-B0118 anti-mouse NK-1.1 PK136 PG
TotalSeq™-C0118 anti-mouse NK-1.1 PK136 PG
PE/Fire™ 810 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 640 anti-mouse NK-1.1 PK136 FC
Spark UV™ 387 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 700 anti-mouse NK-1.1 PK136 FC
Go To Top Version: 2    Revision Date: 12/08/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account